Abstract
Information regarding the pharmacokinetics of oral sildenafil in dogs with pulmonary hypertension is limited. In this study, we examined the pharmacokinetics of oral sildenafil in a canine model of chronic embolic pulmonary hypertension (CEPH). The CEPH model was developed by repeatedly injecting microspheres into the pulmonary arteries. The pharmacokinetics of oral sildenafil at 1, 2 and 4 mg/kg was evaluated using four dogs with pulmonary hypertension in the fasted state. The plasma concentrations of sildenafil were determined using high-performance liquid chromatography, and pharmacokinetic parameters were calculated using a noncompartmental analysis. Sildenafil was well tolerated in this study. Proportional increments in the maximum plasma concentration and area under the curve extrapolated to infinity at drug doses of 1, 2 and 4 mg/kg were detected using a power model analysis. No significant differences were observed among the three doses in the time to maximum plasma concentration. The mean residence time and elimination half-life were slightly but significantly higher at a dose of 4 mg/kg than at a dose of 1 mg/kg.
Author supplied keywords
Cite
CITATION STYLE
Akabane, R., Sato, T., Sakatani, A., Ogawa, M., Nagakawa, M., Miyakawa, H., … Takemura, N. (2020). Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension. Journal of Veterinary Medical Science, 82(4), 446–451. https://doi.org/10.1292/jvms.19-0595
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.